Cardiac MRI for the evaluation of oncologic cardiotoxicity
- 256 Downloads
Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-established adverse effect resulting from a number of cancer therapeutics. Newer immunotherapy has been associated with cardiomyopathy and myocarditis making comprehensive imaging useful for early recognition. Cardiac MRI (CMR) offers a comprehensive evaluation to detect CTRCD. Established guidelines for monitoring left ventricular ejection fraction for potential cardiotoxicity have recently incorporated CMR. We will review the utility of CMR in contemporary evaluation for potential oncologic cardiotoxicity.
KeywordsCardiac MRI cardio-oncology cardiac toxicity
Cancer therapeutics-related cardiac dysfunction
Extracelluar volume fraction
Global longitudinal strain
Late gadolinium enhancement
MS receives grant support from Astra Zeneca and research support from Siemens. MS is supported in part by NIH R01 HL131919, and AL is supported by NIH 5T32EB003841.
- 8.Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr 2014;27:911-39.CrossRefGoogle Scholar
- 14.Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77-84.CrossRefGoogle Scholar
- 17.Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for cardiovascular magnetic resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson 2013. https://doi.org/10.1186/1532-429X-15-35.Google Scholar
- 19.Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:29-34.CrossRefGoogle Scholar
- 20.Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II—Positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.CrossRefGoogle Scholar
- 25.Jordan JH, Sukpraphrute B, Melendez GC, Jolly MP, D’Agostino RB Jr, Hundley WG. Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: The need to interpret left ventricular strain with volumes. Circulation 2017;135:2575-7.CrossRefGoogle Scholar
- 41.Jordan JH, Vasu S, Morgan TM, D’Agostino RB Jr, Melendez GC, Hamilton CA, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016. https://doi.org/10.1161/circimaging.115.004325.Google Scholar